<DOC>
	<DOCNO>NCT02139267</DOCNO>
	<brief_summary>The purpose study determine optimal dose GX-188E Phase 3 access efficacy safety GX-188E accord protocol patient Cervical Intraepithelial Neoplasia 3 ( CIN3 ) .</brief_summary>
	<brief_title>Dose-finding , Safety Study Plasmid DNA Therapeutic Vaccine Treat Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>Subjects eligible study allocate one two treatment group GX-188E . All Subject receive GX-188E intramuscularly use electroporator ( EP ) alternate deltoid muscle perform totally three time study period .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Voluntarily sign informed consent form receive education study investigational product . 2 . Female age 19 50 year 3 . Positive test result HPV Type 16 and/or Type 18 4 . Histopathologicallyconfirmed Cervical Intraepithelial Neoplasia 3 5 . Entire cervical area include entire squamocolumnar junction visualize colposcopy 6 . Eligible base screen test result . 7 . Promised get pregnant throughout study 1 . Suspected Adenocarcinoma situ 2 . Malignant cancer Stage I 3 . Pregnancy breastfeed 4 . Participation clinical trial within 30 day screen visit 5 . Administration immunosuppressant immunomodulator within 6 month prior enrolment 6 . Administered systemic steroid ( standard Prednisolone , 20mg/day every 14 day ) within 3 month Day 1 ( include ointment , eye drop , inhalated nasal , intraligamental intraarticular injection , applicable injected every day 7 . Administered blood product within 3 month prior screen visit 8 . Administered vaccine within 4 week prior screen visit ( ex . Hepatitis A , Hepatitis B , Influenza , Td etc . ) 9 . Positive serum test result hepatitis C virus , hepatitis B virus surface antigen ( HBsAg ) HIV 10 . Severe hepatopathy Class C accord ChildPough 's classification 11 . Severe renal dysfunction creatinine clearance ( CLcr ) low 30ml/min 12 . CPK test result 2.5 time upper limit normal 13 . Predisposed inflammatory reaction due use medical device electroporation within 30 day screen visit 14 . History severe adverse drug event severe allergic disease 15 . History epilepsy convulsion within 2 year prior screen visit 16 . At discretion investigator , skin condition cover deltoid muscle , within 2cm intend site injection , suitable injection due infection , ulcer , edema , tattoo , scar , injury etc . 17 . The thickness skin fold cover deltoid muscle , intend injection site , &gt; 40mm 18 . Any orthopedic artificial implant around intend site electroporation ( deltoid muscle ) 19 . Sinus bradycardia whose rest heart rate &lt; 50 beats/min 20 . Preexcitation syndrome WolffParkinsonWhite syndrome 21 . Abnormal electrocardiography ( ECG ) include arrhythmia 22 . Artificial implant metallic implant 23 . Any ineligible condition discretion investigator would ineligible participate study</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CIN3</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>High-Risk HPV</keyword>
	<keyword>HPV Infection</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Precancerous Diseases</keyword>
	<keyword>Uterine Diseases</keyword>
	<keyword>Genital Diseases , Female</keyword>
</DOC>